非小细胞肺癌的分子靶向治疗  

Molecular targeted therapy of non-small cell lung cancer

作　　者：南兆棣 陈绍水[1] Nan Zhaodi, Chen Shaoshui.(Department of Oncology, Affiliated Hospital of Binzhou Medical University, Binzhou 256600, Chin)

机构地区：[1]滨州医学院附属医院肿瘤科,256600

出　　处：《国际肿瘤学杂志》2018年第1期39-43,共5页Journal of International Oncology

摘　　要：目前非小细胞肺癌（NSCLC）的治疗已经进入靶向治疗时代，小分子酪氨酸激酶抑制剂为典型代表，它们有明确的分子靶标并且疗效显著，但许多基因未突变的患者不能从中获益。血管内皮生长因子及免疫靶向治疗成为NSCLC治疗的新焦点，程序性死亡受体1与其配体等抑制剂在一系列NSCLC临床试验中显示出了巨大的应用潜力。At present, the treatment of nonsmall cell lung cancer （NSCLC） has entered the era of targeted therapy, and small molecule tyrosine kinase inhibitors are typical representatives, which have clear molecular targets and remarkable effects. But many patients without mutations are not able to benefit from them. Vascular endothelial growth factor and immune targeted therapy have become the new focus of NSCLC treatment. Inhibitors such as programmed cell death1 and programmed cell deathligand 1 have shown great applied potential in a series of clinical trials of NSCLC.

关 键 词：癌 非小细胞肺 免疫毒素类 治疗应用 

分 类 号：R734.2[医药卫生—肿瘤]